KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Equity Average: 2009-2025

Historic Equity Average for Novavax (NVAX) over the last 14 years, with Sep 2025 value amounting to -$59.5 million.

  • Novavax's Equity Average rose 87.58% to -$59.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$59.5 million, marking a year-over-year increase of 87.58%. This contributed to the annual value of -$670.4 million for FY2024, which is 0.76% up from last year.
  • Per Novavax's latest filing, its Equity Average stood at -$59.5 million for Q3 2025, which was down 213.13% from -$19.0 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Equity Average registered a high of $892.3 million during Q2 2021, and its lowest value of -$825.1 million during Q2 2023.
  • Over the past 3 years, Novavax's median Equity Average value was -$649.4 million (recorded in 2024), while the average stood at -$538.9 million.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 1,011.57% in 2021, then tumbled by 1,194.32% in 2022.
  • Quarterly analysis of 5 years shows Novavax's Equity Average stood at $54.8 million in 2021, then tumbled by 1,194.32% to -$600.0 million in 2022, then dropped by 16.27% to -$697.6 million in 2023, then rose by 17.56% to -$575.1 million in 2024, then surged by 87.58% to -$59.5 million in 2025.
  • Its Equity Average was -$59.5 million in Q3 2025, compared to -$19.0 million in Q2 2025 and -$349.7 million in Q1 2025.